Impact of the CCP test on physician and patient treatment selection for localized prostate cancer.

The CCP test is a validated molecular assay that assesses prostate cancer-specific disease progression and mortality risk when combined with clinicopathologic parameters.

The results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the CCP test regarding shared treatment decision making for newly diagnosed prostate cancer patients, are presented here.

Materials and Methods: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled and the CCP test was performed on the initial prostate biopsy tissue. A set of four sequential surveys tracked changes relative to initial therapy recommendations (pre-CCP) based on clinopathologic parameters following: physician review of the CCP test result, physician/patient review of the CCP test results, and a minimum of three-months of clinical follow-up (actual treatment).

Results: 1206/1596 patients enrolled in this registry were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (P<0.0001), with mean number of treatments per patient decreasing from 1.72 pre-CCP test to 1.16 in actual follow-up. The CCP test caused a change in actual treatment in 47.8% of patients. Of these changes, 72.1% were reductions and 26.9% were increases in treatment. For each clinical risk category, there was a significant change in treatment modality (intervention vs. non-intervention) pre-CCP to post-CCP testing (P=0.0002).

Conclusions: The CCP test has a significant impact in assisting physicians and patients reach personalized treatment decisions.

The Journal of urology. 2015 Sep 21 [Epub ahead of print]

Neal D Shore, Naveen Kella, Brian Moran, Judd Boczko, Fernando J Bianco, E David Crawford, Thaylon Davis, Kirstin M Roundy, Kristen Rushton, Charles Grier, Rajesh Kaldate, Michael K Brawer, Mark L Gonzalgo

Carolina Urologic Research Center, Myrtle Beach, SC. The Urology and Prostate Institute, San Antonio, TX. , Prostate Cancer Foundation of Chicago, Westmont, IL. , WESTMED Medical Group, Woodmere, NY. , Urological Research Network, Miami Lakes, FL. , University of Colorado at Denver, Aurora, CO. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , Myriad Genetic Laboratories, Inc. , Salt Lake City, UT. , University of Miami Miller School of Medicine, Miami, FL.

 Read the Beyond the Abstract

PubMed